Guttenplan, Kevin A. http://orcid.org/0000-0003-4242-4349
Weigel, Maya K.
Prakash, Priya http://orcid.org/0000-0003-2193-9669
Wijewardhane, Prageeth R. http://orcid.org/0000-0002-9781-3053
Hasel, Philip http://orcid.org/0000-0003-4378-3685
Rufen-Blanchette, Uriel
Münch, Alexandra E. http://orcid.org/0000-0002-9609-3277
Blum, Jacob A.
Fine, Jonathan
Neal, Mikaela C.
Bruce, Kimberley D.
Gitler, Aaron D. http://orcid.org/0000-0001-8603-1526
Chopra, Gaurav http://orcid.org/0000-0003-0942-7898
Liddelow, Shane A. http://orcid.org/0000-0002-0840-1437
Barres, Ben A.
Article History
Received: 6 January 2021
Accepted: 26 August 2021
First Online: 6 October 2021
Competing interests
: A.D.G. has served as a consultant for Aquinnah Pharmaceuticals, Prevail Therapeutics and Third Rock Ventures, and is a scientific founder of Maze Therapeutics. S.A.L. is an academic founder of AstronauTx. B.A.B. is a co-founder of Annexon Biosciences, a company working to make new drugs for the treatment of neurological diseases. G.C. is the Director of the Merck-Purdue Center for Measurement Science funded by Merck Sharp & Dohme, a subsidiary of Merck. The remaining authors declare no competing interests.